SCHEMBL19002333

SCHEMBL19002333

Cc1ccc(OC(C)c2ccccc2)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.42
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
HSD17B10 Q99714 1/20 0.40
HTR6 P50406 3/20 0.38
RORC P51449 1/20 0.38
ALKBH1 Q13686 1/20 0.37
S1PR2 O95136 1/20 0.37
S1PR4 O95977 1/20 0.37
S1PR3 Q99500 1/20 0.37
CCR1 P32246 1/20 0.36
CCR5 P51681 1/20 0.36
CCR8 P51685 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1680997 0.80 KDM4E (0.35) ALDH1A1KDM4EHSD17B10CCR1CCR5
SCHEMBL18997065 0.79 NUDT1 (0.40) NUDT1ADRA2AADRA2BADRA2CALDH1A1
SCHEMBL6938238 0.77 ALDH1A1 (0.50) ALDH1A1KDM4EHSD17B10CCR1CCR5
SCHEMBL21494388 0.77 ADRA2A (0.47) NUDT1ADRA2AADRA2BADRA2CALDH1A1
SCHEMBL19122787 0.76 CCR1 (0.43) ADRA2AADRA2BADRA2CALDH1A1KDM4E
SCHEMBL19122859 0.76 CCR1 (0.43) ADRA2AADRA2BADRA2CALDH1A1KDM4E
SCHEMBL18726999 0.74 CCR1 (0.41) ADRA2AADRA2BADRA2CALDH1A1KDM4E
SCHEMBL21900738 0.74 HPGD (0.37) NUDT1ADRA2AADRA2BADRA2CHTR6
SCHEMBL26524482 0.74 CCR1 (0.41) ADRA2AADRA2BADRA2CALDH1A1KDM4E
SCHEMBL4539717 0.73 PKM (0.44) ALDH1A1KDM4EHSD17B10HDAC6POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE MAPK6, MAP3K6, MAPK4 NUDT1 1968/4885ADRA2A 4315/4885ADRA2B 4143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.